Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

Michael A. Badruddoja; Marjorie Pazzi; Abhay Sanan; Kurt Schroeder; Kevin Kuzma; Thomas Norton; Thomas Scully; Daruka Mahadevan; Michael Malek Ahmadi

doi:10.1007/s00280-017-3448-9

Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

Michael A. Badruddoja
, Marjorie Pazzi
, Abhay Sanan
, Kurt Schroeder
, Kevin Kuzma
, Thomas Norton
, Thomas Scully
, Daruka Mahadevan
, Michael Malek Ahmadi

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

Original language	English (US)
Pages (from-to)	223
Number of pages	1
Journal	Cancer chemotherapy and pharmacology
Volume	81
Issue number	1
DOIs	https://doi.org/10.1007/s00280-017-3448-9
State	Published - Jan 1 2018
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Oncology
Cancer Research
Toxicology
Pharmacology

Access to Document

10.1007/s00280-017-3448-9

Fingerprint

Dive into the research topics of 'Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)'. Together they form a unique fingerprint.

Cite this

Badruddoja, M. A., Pazzi, M., Sanan, A., Schroeder, K., Kuzma, K., Norton, T., Scully, T., Mahadevan, D., & Ahmadi, M. M. (2018). Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7). Cancer chemotherapy and pharmacology, 81(1), 223. https://doi.org/10.1007/s00280-017-3448-9

Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7). / Badruddoja, Michael A.; Pazzi, Marjorie; Sanan, Abhay et al.
In: Cancer chemotherapy and pharmacology, Vol. 81, No. 1, 01.01.2018, p. 223.

Research output: Contribution to journal › Comment/debate › peer-review

Badruddoja, MA, Pazzi, M, Sanan, A, Schroeder, K, Kuzma, K, Norton, T, Scully, T, Mahadevan, D & Ahmadi, MM 2018, 'Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)', Cancer chemotherapy and pharmacology, vol. 81, no. 1, pp. 223. https://doi.org/10.1007/s00280-017-3448-9

Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T et al. Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7). Cancer chemotherapy and pharmacology. 2018 Jan 1;81(1):223. doi: 10.1007/s00280-017-3448-9

@article{e4281c3194394543a1ef9e30e6938739,

title = "Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)",

abstract = "The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].",

author = "Badruddoja, \{Michael A.\} and Marjorie Pazzi and Abhay Sanan and Kurt Schroeder and Kevin Kuzma and Thomas Norton and Thomas Scully and Daruka Mahadevan and Ahmadi, \{Michael Malek\}",

note = "Publisher Copyright: {\textcopyright} Springer-Verlag GmbH Germany 2017.",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/s00280-017-3448-9",

language = "English (US)",

volume = "81",

pages = "223",

journal = "Cancer chemotherapy and pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

AU - Badruddoja, Michael A.

AU - Pazzi, Marjorie

AU - Sanan, Abhay

AU - Schroeder, Kurt

AU - Kuzma, Kevin

AU - Norton, Thomas

AU - Scully, Thomas

AU - Mahadevan, Daruka

AU - Ahmadi, Michael Malek

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

AB - The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

UR - https://www.scopus.com/pages/publications/85031502938

UR - https://www.scopus.com/pages/publications/85031502938#tab=citedBy

U2 - 10.1007/s00280-017-3448-9

DO - 10.1007/s00280-017-3448-9

M3 - Comment/debate

C2 - 29034406

AN - SCOPUS:85031502938

SN - 0344-5704

VL - 81

SP - 223

JO - Cancer chemotherapy and pharmacology

JF - Cancer chemotherapy and pharmacology

IS - 1

ER -

Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this